Rachael Guenter

Dr. Rachael Guenter

Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
orcid

Research Focus & Metrics

Representative Publications

View All Publications
16 February 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
AAAbdellah Akil
Abdellah Akil
AGAna K. Gutiérrez-García
Ana K. Gutiérrez-García
RGRachael Guenter
Rachael Guenter
JRJ. Bart Rose
J. Bart Rose
ABAdam W. Beck
Adam W. Beck
BRBin Ren
Bin Ren
The Notch signaling pathway plays an essential role in a wide variety of biological processes including cell fate determination of vascular endothelial cells and the regulation of arterial differentiation and angiogenesis. The Notch pathway is also an essential regulator of tumor growth and survival by functioning as either an oncogene or a tumor suppressor in a context-dependent manner. Crosstalk between the Notch and other signaling pathways is also pivotal in tumor progression by promoting cancer cell growth, migration, invasion, metastasis, tumor angiogenesis, and the expansion of cancer stem cells (CSCs). In this review, we provide an overview and update of Notch signaling in endothelial cell fate determination and functioning, angiogenesis, and tumor progression, particularly in the development of CSCs and therapeutic resistance. We further summarize recent studies on how endothelial signaling crosstalk with the Notch pathway contributes to tumor angiogenesis and the development of CSCs, thereby providing insights into vascular biology within the tumor microenvironment and tumor progression.

9 October 2020
Verified
Book Chapter
Closed access
PDF file
RGRachael Guenter
Rachael Guenter
ZPZeelu Patel
Zeelu Patel
HCHerbert Chen
Herbert Chen

15 December 2023 in Endocrine Abstracts
Verified
Journal Article
Closed access
RGRachael Guenter
Rachael Guenter
WCWeisheng Chen
Weisheng Chen
YGYuvasri Golivi
Yuvasri Golivi
MRMario Robledo
Mario Robledo
RJRenata Jaskula-Sztul
Renata Jaskula-Sztul
BRBart Rose
Bart Rose
Background: The 5-year survival rate for patients with advanced pancreatic neuroendocrine tumors (pNETs) is less than 30%. Notch signaling is a transmembrane receptor pathway with four distinct isoforms, activation of which is linked to cellular differentiation, cell fate, and viability. Both Notch1 and Notch3 signaling have been shown to be dysregulated in pNETs. Notch3 activation has been shown to repress Notch1 activity in other cancers. We hypothesize that activation of Notch3 can reduce Notch1-mediated proliferation in pNETs. Methods: Genetic deletion of Notch1 (N1-KO) in a pNET cell line (BON) was achieved using CRISPR/Cas9 to create a compound heterozygous knockout at exon 3. An inducible Notch1 overexpression cell line was generated by stably transfecting BON with a plasmid construct containing the Notch1 active form (N1ICD) under a Tet-On regulator. A constitutively on Notch3 cell line was generated by lentiviral transduction of BON with a plasmid overexpressing the Notch3 active form (N3ICD). Real-time quantitative PCR was used to measure mRNA transcript levels, and western blot was used to measure protein expression. Two-dimensional (2D) viability was measured by MTT assay, and three-dimensional (3D) proliferation was measured by spheroid size. Results: We found that deletion of Notch1 reduced the expression of Notch3 at both the mRNA and protein levels. Increased cell density (ligand availability) or treatment with valproic acid (known Notch1 inducer) lead to increased N3ICD in wild-type (WT) BON but not in N1-KO. Overexpression of N1ICD was associated with increased expression of known downstream target Hes1, as well as Notch3. In contrast, forced overexpression of N3ICD lead to increased Notch1 expression but not Hes1 when compared to a BON cell line transfected with an empty vector. Functionally, N1-KO and N3ICD overexpression cells both had reduced proliferation in both 2D and 3D cell culture. Conclusion: The Notch1 and Notch3 receptors produce signaling cascades that regulate growth in pNET cells through distinct mechanisms. Reduction of Notch1 signaling suppresses growth, while the same effect can be achieved with Notch3 overexpression. Thus, specifically upregulating Notch3 may be a strategy to block Notch1-mediated proliferation in pNET cells. Abstract ID 23724

22 March 2024 in Cancer Research
Verified
Journal Article
Closed access
RGRachael Guenter
Rachael Guenter
WCWeisheng Chen
Weisheng Chen
YGYuvasri Golivi
Yuvasri Golivi
MRMario Robledo
Mario Robledo
CACole Adams
Cole Adams
JRJ. Bart Rose
J. Bart Rose
Background: The 5-year survival rate for patients with advanced pancreatic neuroendocrine tumors (pNETs) is less than 30%. Notch signaling is a transmembrane receptor pathway with four receptor isoforms and five different ligands. Binding between a receptor and ligand triggers pathway activation and is linked to cellular differentiation, cell fate, proliferation, and viability. Both Notch1 and Notch3 signaling have been shown to be dysregulated in pNETs. Notch3 activation has been shown to repress Notch1 activity in other cancers. We hypothesize that activation of Notch3 can reduce Notch1-mediated proliferation in pNETs.Methods: Genetic deletion of Notch1 (N1-KO) in a pNET cell line (BON) was achieved using CRISPR/Cas9 to create a compound heterozygous knockout at exon 3. An inducible Notch1 overexpression cell line was generated by stably transfecting BON with a plasmid construct containing the Notch1 active form (N1ICD) under a Tet-On regulator. A constitutively active Notch3 cell line was generated by lentiviral transduction of BON with a plasmid overexpressing the Notch3 active form (N3ICD). Real-time quantitative PCR was used to measure mRNA transcript levels, and western blot was used to measure protein expression. Two-dimensional (2D) viability was measured by MTT assay, and three-dimensional (3D) proliferation was measured by spheroid size.Results: Genetic knockout of Notch1 (N1-KO) reduced the expression of Notch3 at both mRNA and protein levels. N1-KO had reduced proliferation compared to (WT) BON. Increased cell density (ligand availability) or treatment with valproic acid (known Notch1 inducer) led to increased N3ICD in WT BON but not in N1-KO. Overexpression of N1ICD was associated with increased expression of a known downstream target Hes1, as well as Notch3. In contrast, forced overexpression of N3ICD led to increased Notch1 expression, but not Hes1 when compared to a BON cell line transfected with an empty vector. Functionally, N1-KO and N3ICD overexpression cells both had reduced proliferation in both 2D and 3D cell culture.Conclusions: The Notch1 and Notch3 receptors produce signaling cascades that regulate growth in pNET cells through distinct mechanisms. Reduction of Notch1 signaling suppresses growth, while the same effect can be achieved with Notch3 overexpression. Thus, specifically upregulating Notch3 may be a strategy to block Notch1-mediated proliferation in pNET cells.Citation Format: Rachael Guenter, Weisheng Chen, Yuvasri Golivi, Mario Robledo, Cole Adams, Renata Jaskula-Sztul, Herbert Chen, J. Bart Rose. Interplay of Notch1 and Notch3 signaling regulates pancreatic neuroendocrine tumor proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4387. Background: The 5-year survival rate for patients with advanced pancreatic neuroendocrine tumors (pNETs) is less than 30%. Notch signaling is a transmembrane receptor pathway with four receptor isoforms and five different ligands. Binding between a receptor and ligand triggers pathway activation and is linked to cellular differentiation, cell fate, proliferation, and viability. Both Notch1 and Notch3 signaling have been shown to be dysregulated in pNETs. Notch3 activation has been shown to repress Notch1 activity in other cancers. We hypothesize that activation of Notch3 can reduce Notch1-mediated proliferation in pNETs.Methods: Genetic deletion of Notch1 (N1-KO) in a pNET cell line (BON) was achieved using CRISPR/Cas9 to create a compound heterozygous knockout at exon 3. An inducible Notch1 overexpression cell line was generated by stably transfecting BON with a plasmid construct containing the Notch1 active form (N1ICD) under a Tet-On regulator. A constitutively active Notch3 cell line was generated by lentiviral transduction of BON with a plasmid overexpressing the Notch3 active form (N3ICD). Real-time quantitative PCR was used to measure mRNA transcript levels, and western blot was used to measure protein expression. Two-dimensional (2D) viability was measured by MTT assay, and three-dimensional (3D) proliferation was measured by spheroid size.Results: Genetic knockout of Notch1 (N1-KO) reduced the expression of Notch3 at both mRNA and protein levels. N1-KO had reduced proliferation compared to (WT) BON. Increased cell density (ligand availability) or treatment with valproic acid (known Notch1 inducer) led to increased N3ICD in WT BON but not in N1-KO. Overexpression of N1ICD was associated with increased expression of a known downstream target Hes1, as well as Notch3. In contrast, forced overexpression of N3ICD led to increased Notch1 expression, but not Hes1 when compared to a BON cell line transfected with an empty vector. Functionally, N1-KO and N3ICD overexpression cells both had reduced proliferation in both 2D and 3D cell culture.Conclusions: The Notch1 and Notch3 receptors produce signaling cascades that regulate growth in pNET cells through distinct mechanisms. Reduction of Notch1 signaling suppresses growth, while the same effect can be achieved with Notch3 overexpression. Thus, specifically upregulating Notch3 may be a strategy to block Notch1-mediated proliferation in pNET cells.Citation Format: Rachael Guenter, Weisheng Chen, Yuvasri Golivi, Mario Robledo, Cole Adams, Renata Jaskula-Sztul, Herbert Chen, J. Bart Rose. Interplay of Notch1 and Notch3 signaling regulates pancreatic neuroendocrine tumor proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4387.

15 December 2023 in Endocrine Abstracts
Verified
Journal Article
Closed access
WCWeisheng Chen
Weisheng Chen
RGRachael Guenter
Rachael Guenter
BHBrendon Herring
Brendon Herring
YGYuvasri Golivi
Yuvasri Golivi
JWJason Whitt
Jason Whitt
BRBart Rose
Bart Rose
Background: Cancer cells utilize both oxidative phosphorylation (OXPHOS) and glycolysis to generate energy. Switching between OXPHOS and glycolysis can promote tumor progression. The mechanisms governing oncogenic metabolic flexibility are largely unknown, but recent data has suggested that Notch1 dysregulation in cancer cells can contribute to altered metabolic phenotypes. We hypothesized that Notch1 signaling supports metabolic flexibility in pancreatic neuroendocrine tumor (pNET) cells. Methods: We established a Notch1-knockout (N1-KO) pNET cell line by deleting Notch1 at exon 3 in BON cells using CRISPR/Cas9. Seahorse Glycolytic Rate Assay and Mitochondria Stress Test were used to measure the glycolytic and mitochondrial activities of cells. A glycolysis deprivation assay was employed to determine cell viability at varying glucose concentrations. Single end RNAseq was performed using the Illumina NGS platform, to a read depth of 50M. Results: Compared to wild-type (WT) BON, the N1-KO cells had reduced basal oxygen consumption rate (28.2 ± 1.3 vs. 40.7 ± 1.4; P =0.02, ATP production (21.9 ± 1.0 vs. 29.6 ± 0.98; P =0.04), and maximal respiration (39.4 ± 1.7 vs. 63.7 ± 2.1; P =0.004). N1-KO cells also had a reduction in basal glycolysis, as measured by proton efflux rate, compared to WT (48.7 ± 2.6 vs. 57.7 ± 6.2; P=0.2). To test metabolic flexibility, WT and N1-KO cells were starved of glucose (0mM), compared to normal glucose (17.5mM) and viability was measured over time. By day 5, the N1-KO group had a viability of 0%, whereas 13% of WT cells were alive. To determine if Notch1 loss was associated with altered expression of established metabolic genes, we performed RNAseq on WT and N1-KO cells. Differential gene expression analysis found multiple OXPHOS-related genes (UQCC2, COX15, COX20) and glycolysis-related genes (Slc1a1, Slc2a4, Hk1, Hk2) were significantly down-regulated in N1-KO cells. Conclusion: Our study shows that Notch1 signaling facilitates metabolic reprogramming as a survival advantage in pNET cells. Targeting Notch1 signaling to mediate cellular metabolism may be a novel therapeutic strategy in pNETs. Abstract ID 23738

1 February 2023 in Endocrine Abstracts
Verified
Journal Article
Closed access
WCWeisheng Chen
Weisheng Chen
RGRachael Guenter
Rachael Guenter
BHBrendon Herring
Brendon Herring
RJRenata Jaskula-Sztul
Renata Jaskula-Sztul
RBRose J. Bart
Rose J. Bart
HCHerbert Chen
Herbert Chen
Background: The 5-year survival rate for patients with unresectable, metastatic pancreatic neuroendocrine tumors (pNETs) remains less than 30%, emphasizing the need for new and effective treatment options for patients with advanced pNETs. Notch1 signaling is a critical cell-cell communication pathway responsible for regulating differentiation, cell fate determination, and epithelial-mesenchymal transition (EMT). Notch1 plays a critical role in the differentiation state of NE cells and is aberrantly expressed in metastatic pNETs. We hypothesized that Notch1 signaling plays a role in pNET malignancy. Methods: To characterize the role of Notch1, we developed a Notch1-knockout pNET cell line. The resulting cell line was established by deleting Notch1 at exon 3 in BON cells using CRISPR/Cas9. Successful knockout of Notch1 was confirmed by Sanger sequencing and western blot analyses. To confirm the loss of functional Notch1, we measured changes of specific Notch1 downstream genes at both the transcriptional and translational level. Moreover, to have a global view of signaling pathways affected by Notch1, we performed RNAseq analyses comparing wildtype (N1-WT) and Notch1-knockout cells. Reads were aligned to the transcriptome using STAR and differentially expressed genes (DEG’s) determined using DESeq2. Gene set enrichment analysis was then performed using the Hallmark gene sets. Cell migration was measured by a transwell migration assay. Results: Notch1 knockout was confirmed by a decrease in downstream Hes family genes, and an increase in Ascl1, a gene repressed by Notch. RNAseq results showed an increase in expression of NE differentiation markers in Notch1-knock cells, NeuroD1, which was also confirmed by RT-qPCR. Further, RNAseq analyses showed that when Notch1 is deleted, there was a significant decrease in EMT-related genes (P=0.015). This finding was confirmed with RT-qPCR, whereby Notch1-knockout cells demonstrated a reduction in expression of Snail [two-sample t(4)= 3.957, P=0.017] and Slug [two-sample t(4)= 1.062, P=0.348] compared to N1-WT, two genes linked to cell migration and EMT. Finally, migration assays revealed that significantly fewer Notch1-knockout cells were able to migrate when compared to wildtype [two-sample t(6)= 5.889, P=0.001]. Conclusions: Knockout of Notch1 signaling in pNET cells inhibits migration and reduces expression of EMT-related genes. Our data suggest Notch1 may confer a more aggressive phenotype in pNET cells by facilitating metastatic spread. Inhibiting Notch1 signaling may be an effective therapeutic strategy in advanced pNETs. Abstract ID 21479